A5011631986- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Pneumocystis jirovecii pneumonia detection and treatment
- Acute Myeloid Leukemia Research
- Virus-based gene therapy research
- BRCA gene mutations in cancer
- COVID-19 Clinical Research Studies
- Colorectal Cancer Screening and Detection
- Global Cancer Incidence and Screening
- Healthcare cost, quality, practices
- Nutrition, Genetics, and Disease
- Biomedical Ethics and Regulation
- Colorectal Cancer Treatments and Studies
- Genetics, Bioinformatics, and Biomedical Research
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Viral Infectious Diseases and Gene Expression in Insects
University of San Francisco
2023
Johns Hopkins University
2023
Innsbruck Medical University
2010
Universität Innsbruck
2010
University of Colorado Health
2009
Abstract Background The understanding of the impact COVID‐19 in patients with cancer is evolving, need for rapid analysis. Aims This study aims to compare clinical and demographic characteristics (with without COVID‐19) characterize outcomes cancer. Methods Results Real‐world data (RWD) from two health systems were used identify 146 702 adults diagnosed between 2015 2020; 1267 cases identified February 1 July 30, 2020. Demographic, clinical, socioeconomic extracted. Incidence all‐cause...
African American individuals are disproportionately affected by lung cancer in terms of incidence and mortality. In oncogene-driven non-small-cell (NSCLC), emerging evidence indicates that underlying molecular heterogeneity, which can be ancestry, contributes to variable drug sensitivity therapeutic responses. The purpose this study was evaluate race-associated differences reported treatment decisions, outcomes, features KRAS- EGFR-mutant NSCLC.This is a retrospective using real-world...
Pancreatic cancer is the fourth leading cause of cancer-related death in United States, and even under optimal therapy these patients face a poor prognosis. Here we report novel gene therapy-based strategy to battle this disease. We show that majority pancreatic tumors overexpress c-erb-B2, which therefore might serve as target for therapies. On basis findings, developed an adenoviral vector [Ad-e23(scFv)-PE40] encoding c-erb-B2 (Her-2/neu)-targeted immunotoxin. To improve viral delivery...
Using conditionally replicating adenoviral vectors (CRAds) is a promising strategy in the treatment of solid tumors. The prospective this study was to design novel CRAd for gastrointestinal cancer and show its efficacy vitro, as well vivo. To determine if aberrant wnt signaling tumor cells can be used selectively drive viral replication, we analyzed six colorectal hepatocellular cell lines, 13 tumors 17 gastric tumors, β-catenin mutation status or signaling, both which were found frequently....
Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, incidence treatment-associated pneumonitis (TAP) was compared among with advanced non–small cell lung cancer immune checkpoint inhibitors (ICI) or chemotherapies either two settings: randomized clinical trials (RCT) real world data (RWD)-based practice. cases were identified...
Abstract Introduction: Reports suggest worsened outcomes in patients with cancer (pts) and COVID-19 (Cov), varying by geography local peak dynamics. We describe characteristics clinical of pts without Cov. Methods: RWD at 2 Midwestern health systems from the Syapse Learning Health Network were used to identify adults active (AC) or past history (PHC). AC identified encounters ICD-10 code for malignant neoplasm receipt an anticancer agent within 12 months prior February 15, 2020; PHC May 2015...
9105 Background: Immune checkpoint inhibitor (ICI) therapy has become a mainstay of non-small cell lung cancer (NSCLC) treatment. However, not all patients (pts) benefit with subset paradoxically experiencing accelerated tumor growth while on ICI. Hyperprogression (HP) refers to ICI worsening clinical status. Various gene alterations may be associated HP including MDM2/MDM4 amplifications, EGFR alterations, and STK11/LKB1 mutations. Kato et al. (doi: 10.1158/1078-0432.CCR-16-3133 ) showed in...
<div><p>Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, incidence treatment-associated pneumonitis (TAP) was compared among with advanced non–small cell lung cancer immune checkpoint inhibitors (ICI) or chemotherapies either two settings: randomized clinical trials (RCT) real world data (RWD)-based practice....
<div><p>Pneumonitis is a potentially life-threatening complication of anticancer therapy, and future treatment decisions may be informed by characterizing patients receiving therapies in the real-world setting. In this study, incidence treatment-associated pneumonitis (TAP) was compared among with advanced non–small cell lung cancer immune checkpoint inhibitors (ICI) or chemotherapies either two settings: randomized clinical trials (RCT) real world data (RWD)-based practice....
Abstract Introduction: Health disparities exist for US sexual and gender minorities (SGM) relative to the general population, including cancer screening with variation across disease sites. Limited data describe frequency of guideline-concordant colorectal (CRC) among SGM people, few studies using nationally-representative samples. This study aims assess CRC participation people leveraging health survey data. Methods: Data from 2020 Behavioral Risk Factor Surveillance System (BRFSS) were...
Abstract Background and Objective: BRCA testing for patients (pts) with triple negative breast cancer (TNBC) is important because it has secondary prevention implications multigenerational allowing earlier detection of gene carriers in the family enabling primary prevention. And advent PARP inhibitors also treatment implications. The NCCN guidelines recommended January 2015 that be performed all pts TNBC diagnosed at age 60 or younger regardless race, ethnicity history. To understand...
e21015 Background: African American (AA) individuals are disproportionately affected by lung cancer in terms of incidence and mortality, despite lower tobacco exposure compared to Caucasian Americans (CA). Since molecular profiling is critically important guide therapy selection non-small cell (NSCLC), we treatment-relevant data a cohort AA CA patients with EGFR or KRAS-driven NSCLC. Methods: This retrospective study using clinicogenomic electronic medical record database from health systems...
Abstract Background and Objective: Molecular testing targeted treatments for patients (pts) diagnosed with AML have evolved in recent years. Real-world patterns, including next-generation sequencing (NGS), clinical management of pts were analyzed 2 large U.S. community health systems. Methods: Pts &gt;18 years, from January 1, 2015 to December 31, 2020, identified a database containing genomic data integrated delivery networks. Study end was March 2021, allowing 3 months minimum follow...
e21047 Background: Patients (pts) with lung cancer and other cancers treated immune checkpoint inhibitors (ICI) may experience related adverse events (irAE). These can present variable severity single- or multi-organ involvement including pneumonitis, colitis, hepatitis, myocarditis/pericarditis. The incidence of myocarditis has been reported between 0.06% 2.4% is associated a high mortality (25% to 50%). This retrospective review real-world data (RWD) investigates as high-grade event in pts...
Abstract Background: Molecular tumor boards (MTB) are a key component of most precision oncology programs, designed to provide structured multidisciplinary approach evaluating cancer patients (pts) for therapy (Tx), clinical trial (CT) enrollment, and genetic counseling (GC) services. Two health systems separately instituted MTB in 2017, through bio-informatics platform have been tracking the impact these on pt care. We describe collective experience impact. Methods: This is retrospective...